Search results
Results from the WOW.Com Content Network
This page was last edited on 7 September 2014, at 19:11 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase enzymes MEK1 and/or MEK2. They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers.
The proteinase inhibitors work to disrupt the enzymatic ability of the digestive or microbial enzymes that are present in the stomach of the attacker resulting in the inability to properly digest the plant material. This causes an interference of proper growth and discourages further wounding of the plant by the attacker. [1]
Plants can protect themselves from abiotic stress in many different ways, and most include a physical change in the plant’s morphology. Phenotypic plasticity is a plant’s ability to alter and adapt its morphology in response to the external environments to protect themselves against stress. [ 2 ]
A B-Raf inhibitor is an anticancer drug that inhibits the normal or mutated B-raf gene. Pages in category "B-Raf inhibitors" The following 3 pages are in this category, out of 3 total.
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf. [5] [6] The B-Raf protein is involved in sending signals inside cells which are involved in directing ...
The signal that starts the MAPK/ERK pathway is the binding of extracellular mitogen to a cell surface receptor.This allows a Ras protein (a Small GTPase) to swap a GDP molecule for a GTP molecule, flipping the "on/off switch" of the pathway.
Vemurafenib causes programmed cell death in melanoma cell lines. [3] Vemurafenib interrupts the B-Raf/MEK step on the B-Raf/MEK/ERK pathway − if the B-Raf has the common V600E mutation. Vemurafenib only works in melanoma patients whose cancer has a V600E BRAF mutation (that is, at amino acid position number 600 on the B-Raf protein, the ...